Sema4 Holdings Corp. (SMFR) Stock Competitors & Peer Comparison
See (SMFR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SMFR | $0.31 | +26.78% | 246.4M | N/A | N/A | N/A |
| VEEV | $184.37 | +3.89% | 29.9B | 22.12 | $8.33 | N/A |
| GEHC | $64.86 | +1.33% | 29.5B | 14.22 | $4.56 | +0.22% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| BTSGU | $230.89 | +0.85% | 13.8B | 208.78 | $1.11 | N/A |
| BTSG | $69.85 | +0.16% | 13.7B | 56.33 | $1.24 | N/A |
| TEM | $61.60 | +6.34% | 10.8B | -123.20 | -$0.50 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| HQY | $92.29 | +2.18% | 7.7B | 21.56 | $4.28 | N/A |
| HNGE | $85.13 | +2.57% | 6.6B | 43.66 | $1.95 | N/A |
Stock Comparison
SMFR vs VEEV Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, VEEV has a market cap of 29.9B. Regarding current trading prices, SMFR is priced at $0.31, while VEEV trades at $184.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas VEEV's P/E ratio is 22.12. In terms of profitability, SMFR's ROE is -0.28%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, SMFR is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check VEEV's competition here
SMFR vs GEHC Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, GEHC has a market cap of 29.5B. Regarding current trading prices, SMFR is priced at $0.31, while GEHC trades at $64.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas GEHC's P/E ratio is 14.22. In terms of profitability, SMFR's ROE is -0.28%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, SMFR is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check GEHC's competition here
SMFR vs GEHCV Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, SMFR is priced at $0.31, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas GEHCV's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, SMFR is more volatile compared to GEHCV. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check GEHCV's competition here
SMFR vs BTSGU Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, BTSGU has a market cap of 13.8B. Regarding current trading prices, SMFR is priced at $0.31, while BTSGU trades at $230.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas BTSGU's P/E ratio is 208.78. In terms of profitability, SMFR's ROE is -0.28%, compared to BTSGU's ROE of +0.17%. Regarding short-term risk, SMFR is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check BTSGU's competition here
SMFR vs BTSG Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, BTSG has a market cap of 13.7B. Regarding current trading prices, SMFR is priced at $0.31, while BTSG trades at $69.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas BTSG's P/E ratio is 56.33. In terms of profitability, SMFR's ROE is -0.28%, compared to BTSG's ROE of +0.17%. Regarding short-term risk, SMFR is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check BTSG's competition here
SMFR vs TEM Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, TEM has a market cap of 10.8B. Regarding current trading prices, SMFR is priced at $0.31, while TEM trades at $61.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas TEM's P/E ratio is -123.20. In terms of profitability, SMFR's ROE is -0.28%, compared to TEM's ROE of -0.70%. Regarding short-term risk, SMFR is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check TEM's competition here
SMFR vs SGFY Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, SMFR is priced at $0.31, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas SGFY's P/E ratio is 70.91. In terms of profitability, SMFR's ROE is -0.28%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, SMFR is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SGFY's competition here
SMFR vs HQY Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, HQY has a market cap of 7.7B. Regarding current trading prices, SMFR is priced at $0.31, while HQY trades at $92.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas HQY's P/E ratio is 21.56. In terms of profitability, SMFR's ROE is -0.28%, compared to HQY's ROE of +0.11%. Regarding short-term risk, SMFR is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check HQY's competition here
SMFR vs HNGE Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, HNGE has a market cap of 6.6B. Regarding current trading prices, SMFR is priced at $0.31, while HNGE trades at $85.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas HNGE's P/E ratio is 43.66. In terms of profitability, SMFR's ROE is -0.28%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, SMFR is more volatile compared to HNGE. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check HNGE's competition here
SMFR vs RCM Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, SMFR is priced at $0.31, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas RCM's P/E ratio is -102.21. In terms of profitability, SMFR's ROE is -0.28%, compared to RCM's ROE of +0.00%. Regarding short-term risk, SMFR is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check RCM's competition here
SMFR vs TXG Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, TXG has a market cap of 5B. Regarding current trading prices, SMFR is priced at $0.31, while TXG trades at $39.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas TXG's P/E ratio is -229.71. In terms of profitability, SMFR's ROE is -0.28%, compared to TXG's ROE of -0.03%. Regarding short-term risk, SMFR is more volatile compared to TXG. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check TXG's competition here
SMFR vs DOCS Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, DOCS has a market cap of 4B. Regarding current trading prices, SMFR is priced at $0.31, while DOCS trades at $21.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas DOCS's P/E ratio is 14.11. In terms of profitability, SMFR's ROE is -0.28%, compared to DOCS's ROE of +0.19%. Regarding short-term risk, SMFR is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check DOCS's competition here
SMFR vs ONEM Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, SMFR is priced at $0.31, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas ONEM's P/E ratio is -7.77. In terms of profitability, SMFR's ROE is -0.28%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, SMFR is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check ONEM's competition here
SMFR vs PRVA Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, PRVA has a market cap of 3.4B. Regarding current trading prices, SMFR is priced at $0.31, while PRVA trades at $26.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas PRVA's P/E ratio is 168.00. In terms of profitability, SMFR's ROE is -0.28%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, SMFR is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check PRVA's competition here
SMFR vs HTFL Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, HTFL has a market cap of 2.6B. Regarding current trading prices, SMFR is priced at $0.31, while HTFL trades at $30.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas HTFL's P/E ratio is -15.28. In terms of profitability, SMFR's ROE is -0.28%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, SMFR is more volatile compared to HTFL. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check HTFL's competition here
SMFR vs PINC Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, SMFR is priced at $0.31, while PINC trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas PINC's P/E ratio is 19.22. In terms of profitability, SMFR's ROE is -0.28%, compared to PINC's ROE of -0.02%. Regarding short-term risk, SMFR is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check PINC's competition here
SMFR vs PGNY Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, PGNY has a market cap of 2.3B. Regarding current trading prices, SMFR is priced at $0.31, while PGNY trades at $29.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas PGNY's P/E ratio is 21.50. In terms of profitability, SMFR's ROE is -0.28%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, SMFR is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check PGNY's competition here
SMFR vs WGS Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, WGS has a market cap of 2.1B. Regarding current trading prices, SMFR is priced at $0.31, while WGS trades at $71.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas WGS's P/E ratio is 84.36. In terms of profitability, SMFR's ROE is -0.28%, compared to WGS's ROE of -0.28%. Regarding short-term risk, SMFR is more volatile compared to WGS. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check WGS's competition here
SMFR vs WGSWW Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, WGSWW has a market cap of 1.8B. Regarding current trading prices, SMFR is priced at $0.31, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas WGSWW's P/E ratio is -0.09. In terms of profitability, SMFR's ROE is -0.28%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, SMFR is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check WGSWW's competition here
SMFR vs TDOC Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, TDOC has a market cap of 1.6B. Regarding current trading prices, SMFR is priced at $0.31, while TDOC trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas TDOC's P/E ratio is -10.11. In terms of profitability, SMFR's ROE is -0.28%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, SMFR is more volatile compared to TDOC. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check TDOC's competition here
SMFR vs NXGN Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, SMFR is priced at $0.31, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas NXGN's P/E ratio is -266.00. In terms of profitability, SMFR's ROE is -0.28%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, SMFR is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check NXGN's competition here
SMFR vs AGTI Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, SMFR is priced at $0.31, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas AGTI's P/E ratio is -71.79. In terms of profitability, SMFR's ROE is -0.28%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, SMFR is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check AGTI's competition here
SMFR vs OMDA Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, OMDA has a market cap of 1.3B. Regarding current trading prices, SMFR is priced at $0.31, while OMDA trades at $22.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas OMDA's P/E ratio is 323.14. In terms of profitability, SMFR's ROE is -0.28%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, SMFR is more volatile compared to OMDA. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check OMDA's competition here
SMFR vs NUTX Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, NUTX has a market cap of 1.1B. Regarding current trading prices, SMFR is priced at $0.31, while NUTX trades at $190.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas NUTX's P/E ratio is 14.74. In terms of profitability, SMFR's ROE is -0.28%, compared to NUTX's ROE of +0.31%. Regarding short-term risk, SMFR is more volatile compared to NUTX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check NUTX's competition here
SMFR vs GDRX Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, GDRX has a market cap of 1.1B. Regarding current trading prices, SMFR is priced at $0.31, while GDRX trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas GDRX's P/E ratio is 9.27. In terms of profitability, SMFR's ROE is -0.28%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, SMFR is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check GDRX's competition here
SMFR vs CERT Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, CERT has a market cap of 1B. Regarding current trading prices, SMFR is priced at $0.31, while CERT trades at $6.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas CERT's P/E ratio is 17.26. In terms of profitability, SMFR's ROE is -0.28%, compared to CERT's ROE of -0.01%. Regarding short-term risk, SMFR is more volatile compared to CERT. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CERT's competition here
SMFR vs CCLDO Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, SMFR is priced at $0.31, while CCLDO trades at $27.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas CCLDO's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, SMFR is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CCLDO's competition here
SMFR vs HSTM Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, HSTM has a market cap of 826.2M. Regarding current trading prices, SMFR is priced at $0.31, while HSTM trades at $28.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas HSTM's P/E ratio is 37.21. In terms of profitability, SMFR's ROE is -0.28%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, SMFR is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check HSTM's competition here
SMFR vs PHR Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, PHR has a market cap of 663.2M. Regarding current trading prices, SMFR is priced at $0.31, while PHR trades at $10.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas PHR's P/E ratio is 38.32. In terms of profitability, SMFR's ROE is -0.28%, compared to PHR's ROE of +0.03%. Regarding short-term risk, SMFR is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check PHR's competition here
SMFR vs EVH Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, EVH has a market cap of 645.1M. Regarding current trading prices, SMFR is priced at $0.31, while EVH trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas EVH's P/E ratio is 573.50. In terms of profitability, SMFR's ROE is -0.28%, compared to EVH's ROE of -0.78%. Regarding short-term risk, SMFR is more volatile compared to EVH. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check EVH's competition here
SMFR vs MPLN-WT Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, SMFR is priced at $0.31, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, SMFR is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check MPLN-WT's competition here
SMFR vs ACCD Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, SMFR is priced at $0.31, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas ACCD's P/E ratio is -3.08. In terms of profitability, SMFR's ROE is -0.28%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, SMFR is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check ACCD's competition here
SMFR vs CCLDP Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, CCLDP has a market cap of 566.6M. Regarding current trading prices, SMFR is priced at $0.31, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas CCLDP's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, SMFR is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CCLDP's competition here
SMFR vs CTEV Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, CTEV has a market cap of 552.4M. Regarding current trading prices, SMFR is priced at $0.31, while CTEV trades at $32.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas CTEV's P/E ratio is -2.49. In terms of profitability, SMFR's ROE is -0.28%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, SMFR is more volatile compared to CTEV. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CTEV's competition here
SMFR vs SHCR Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, SMFR is priced at $0.31, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas SHCR's P/E ratio is -3.76. In terms of profitability, SMFR's ROE is -0.28%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, SMFR is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SHCR's competition here
SMFR vs NRC Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, NRC has a market cap of 503.5M. Regarding current trading prices, SMFR is priced at $0.31, while NRC trades at $22.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas NRC's P/E ratio is 25.39. In terms of profitability, SMFR's ROE is -0.28%, compared to NRC's ROE of +0.57%. Regarding short-term risk, SMFR is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check NRC's competition here
SMFR vs SLGCW Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, SMFR is priced at $0.31, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, SMFR's ROE is -0.28%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, SMFR is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check SLGCW's competition here
SMFR vs SLGC Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, SMFR is priced at $0.31, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas SLGC's P/E ratio is -3.04. In terms of profitability, SMFR's ROE is -0.28%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, SMFR is more volatile compared to SLGC. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SLGC's competition here
SMFR vs TBRG Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, TBRG has a market cap of 393.4M. Regarding current trading prices, SMFR is priced at $0.31, while TBRG trades at $26.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas TBRG's P/E ratio is 9.37. In terms of profitability, SMFR's ROE is -0.28%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, SMFR is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check TBRG's competition here
SMFR vs SOPH Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, SOPH has a market cap of 384.2M. Regarding current trading prices, SMFR is priced at $0.31, while SOPH trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas SOPH's P/E ratio is -10.75. In terms of profitability, SMFR's ROE is -0.28%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, SMFR is more volatile compared to SOPH. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SOPH's competition here
SMFR vs MPLN Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, SMFR is priced at $0.31, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas MPLN's P/E ratio is -0.23. In terms of profitability, SMFR's ROE is -0.28%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, SMFR is more volatile compared to MPLN. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check MPLN's competition here
SMFR vs SLP Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, SLP has a market cap of 370.8M. Regarding current trading prices, SMFR is priced at $0.31, while SLP trades at $18.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas SLP's P/E ratio is 17.82. In terms of profitability, SMFR's ROE is -0.28%, compared to SLP's ROE of -0.49%. Regarding short-term risk, SMFR is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SLP's competition here
SMFR vs TRHC Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, SMFR is priced at $0.31, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas TRHC's P/E ratio is -4.27. In terms of profitability, SMFR's ROE is -0.28%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, SMFR is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check TRHC's competition here
SMFR vs SY Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, SY has a market cap of 223.1M. Regarding current trading prices, SMFR is priced at $0.31, while SY trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas SY's P/E ratio is -5.15. In terms of profitability, SMFR's ROE is -0.28%, compared to SY's ROE of -0.16%. Regarding short-term risk, SMFR is more volatile compared to SY. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SY's competition here
SMFR vs SPOK Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, SPOK has a market cap of 220.8M. Regarding current trading prices, SMFR is priced at $0.31, while SPOK trades at $10.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas SPOK's P/E ratio is 17.62. In terms of profitability, SMFR's ROE is -0.28%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, SMFR is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SPOK's competition here
SMFR vs AMWL Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, AMWL has a market cap of 157.1M. Regarding current trading prices, SMFR is priced at $0.31, while AMWL trades at $9.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas AMWL's P/E ratio is -1.81. In terms of profitability, SMFR's ROE is -0.28%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, SMFR is more volatile compared to AMWL. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check AMWL's competition here
SMFR vs HCAT Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, HCAT has a market cap of 153M. Regarding current trading prices, SMFR is priced at $0.31, while HCAT trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas HCAT's P/E ratio is 10.35. In terms of profitability, SMFR's ROE is -0.28%, compared to HCAT's ROE of -1.00%. Regarding short-term risk, SMFR is more volatile compared to HCAT. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check HCAT's competition here
SMFR vs CPSI Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, SMFR is priced at $0.31, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas CPSI's P/E ratio is -183.80. In terms of profitability, SMFR's ROE is -0.28%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, SMFR is more volatile compared to CPSI. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CPSI's competition here
SMFR vs AUGX Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, SMFR is priced at $0.31, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas AUGX's P/E ratio is -4.99. In terms of profitability, SMFR's ROE is -0.28%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, SMFR is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check AUGX's competition here
SMFR vs OPRX Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, OPRX has a market cap of 114.1M. Regarding current trading prices, SMFR is priced at $0.31, while OPRX trades at $6.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas OPRX's P/E ratio is 5.58. In terms of profitability, SMFR's ROE is -0.28%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, SMFR is more volatile compared to OPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check OPRX's competition here
SMFR vs CCLD Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, CCLD has a market cap of 96.5M. Regarding current trading prices, SMFR is priced at $0.31, while CCLD trades at $2.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas CCLD's P/E ratio is 6.88. In terms of profitability, SMFR's ROE is -0.28%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, SMFR is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CCLD's competition here
SMFR vs DH Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, DH has a market cap of 84.4M. Regarding current trading prices, SMFR is priced at $0.31, while DH trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas DH's P/E ratio is 3.08. In terms of profitability, SMFR's ROE is -0.28%, compared to DH's ROE of -0.67%. Regarding short-term risk, SMFR is more volatile compared to DH. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check DH's competition here
SMFR vs FORA Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, SMFR is priced at $0.31, while FORA trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas FORA's P/E ratio is -24.11. In terms of profitability, SMFR's ROE is -0.28%, compared to FORA's ROE of -0.17%. Regarding short-term risk, SMFR is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check FORA's competition here
SMFR vs ONMD Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, ONMD has a market cap of 39.7M. Regarding current trading prices, SMFR is priced at $0.31, while ONMD trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas ONMD's P/E ratio is -4.86. In terms of profitability, SMFR's ROE is -0.28%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, SMFR is more volatile compared to ONMD. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check ONMD's competition here
SMFR vs SNCE Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, SMFR is priced at $0.31, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas SNCE's P/E ratio is -0.27. In terms of profitability, SMFR's ROE is -0.28%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, SMFR is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SNCE's competition here
SMFR vs AKLI Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, SMFR is priced at $0.31, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas AKLI's P/E ratio is -0.71. In terms of profitability, SMFR's ROE is -0.28%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, SMFR is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check AKLI's competition here
SMFR vs SHLT Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, SMFR is priced at $0.31, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas SHLT's P/E ratio is -3.87. In terms of profitability, SMFR's ROE is -0.28%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, SMFR is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SHLT's competition here
SMFR vs SHCRW Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, SMFR is priced at $0.31, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, SMFR's ROE is -0.28%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, SMFR is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SHCRW's competition here
SMFR vs ONMDW Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, ONMDW has a market cap of 31.4M. Regarding current trading prices, SMFR is priced at $0.31, while ONMDW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas ONMDW's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, SMFR is more volatile compared to ONMDW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check ONMDW's competition here
SMFR vs EUDA Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, EUDA has a market cap of 28M. Regarding current trading prices, SMFR is priced at $0.31, while EUDA trades at $14.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas EUDA's P/E ratio is -2.75. In terms of profitability, SMFR's ROE is -0.28%, compared to EUDA's ROE of +0.13%. Regarding short-term risk, SMFR is more volatile compared to EUDA. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check EUDA's competition here
SMFR vs STRM Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, SMFR is priced at $0.31, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas STRM's P/E ratio is -2.40. In terms of profitability, SMFR's ROE is -0.28%, compared to STRM's ROE of -0.32%. Regarding short-term risk, SMFR is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check STRM's competition here
SMFR vs RNLX Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, SMFR is priced at $0.31, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas RNLX's P/E ratio is -0.33. In terms of profitability, SMFR's ROE is -0.28%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, SMFR is more volatile compared to RNLX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check RNLX's competition here
SMFR vs LIFW Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, SMFR is priced at $0.31, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas LIFW's P/E ratio is -0.02. In terms of profitability, SMFR's ROE is -0.28%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, SMFR is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check LIFW's competition here
SMFR vs BEATW Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, BEATW has a market cap of 20.4M. Regarding current trading prices, SMFR is priced at $0.31, while BEATW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas BEATW's P/E ratio is -0.06. In terms of profitability, SMFR's ROE is -0.28%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, SMFR is more volatile compared to BEATW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check BEATW's competition here
SMFR vs BBLN Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, SMFR is priced at $0.31, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas BBLN's P/E ratio is -0.04. In terms of profitability, SMFR's ROE is -0.28%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, SMFR is more volatile compared to BBLN. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check BBLN's competition here
SMFR vs ETAO Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, SMFR is priced at $0.31, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas ETAO's P/E ratio is -0.01. In terms of profitability, SMFR's ROE is -0.28%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, SMFR is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check ETAO's competition here
SMFR vs BFRG Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, BFRG has a market cap of 8.3M. Regarding current trading prices, SMFR is priced at $0.31, while BFRG trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas BFRG's P/E ratio is -1.31. In terms of profitability, SMFR's ROE is -0.28%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, SMFR is more volatile compared to BFRG. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check BFRG's competition here
SMFR vs HLTH Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, SMFR is priced at $0.31, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas HLTH's P/E ratio is -0.02. In terms of profitability, SMFR's ROE is -0.28%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, SMFR is more volatile compared to HLTH. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check HLTH's competition here
SMFR vs SCNX Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, SCNX has a market cap of 5.5M. Regarding current trading prices, SMFR is priced at $0.31, while SCNX trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas SCNX's P/E ratio is -0.14. In terms of profitability, SMFR's ROE is -0.28%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, SMFR is more volatile compared to SCNX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check SCNX's competition here
SMFR vs UPH Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, SMFR is priced at $0.31, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas UPH's P/E ratio is -0.07. In terms of profitability, SMFR's ROE is -0.28%, compared to UPH's ROE of -1.05%. Regarding short-term risk, SMFR is more volatile compared to UPH. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check UPH's competition here
SMFR vs UPH-WT Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, SMFR is priced at $0.31, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, SMFR is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check UPH-WT's competition here
SMFR vs MGRX Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, MGRX has a market cap of 4.3M. Regarding current trading prices, SMFR is priced at $0.31, while MGRX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas MGRX's P/E ratio is -0.31. In terms of profitability, SMFR's ROE is -0.28%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, SMFR is more volatile compared to MGRX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check MGRX's competition here
SMFR vs PEAR Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, SMFR is priced at $0.31, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas PEAR's P/E ratio is -0.08. In terms of profitability, SMFR's ROE is -0.28%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, SMFR is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check PEAR's competition here
SMFR vs PEARW Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, SMFR is priced at $0.31, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas PEARW's P/E ratio is -0.00. In terms of profitability, SMFR's ROE is -0.28%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, SMFR is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check PEARW's competition here
SMFR vs OTRK Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, SMFR is priced at $0.31, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas OTRK's P/E ratio is -0.02. In terms of profitability, SMFR's ROE is -0.28%, compared to OTRK's ROE of -1.66%. Regarding short-term risk, SMFR is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check OTRK's competition here
SMFR vs HCTI Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, HCTI has a market cap of 2.2M. Regarding current trading prices, SMFR is priced at $0.31, while HCTI trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas HCTI's P/E ratio is -0.02. In terms of profitability, SMFR's ROE is -0.28%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, SMFR is more volatile compared to HCTI. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check HCTI's competition here
SMFR vs VSEE Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, VSEE has a market cap of 1.9M. Regarding current trading prices, SMFR is priced at $0.31, while VSEE trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas VSEE's P/E ratio is -0.22. In terms of profitability, SMFR's ROE is -0.28%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, SMFR is more volatile compared to VSEE. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check VSEE's competition here
SMFR vs ACON Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, ACON has a market cap of 1.6M. Regarding current trading prices, SMFR is priced at $0.31, while ACON trades at $3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas ACON's P/E ratio is -0.29. In terms of profitability, SMFR's ROE is -0.28%, compared to ACON's ROE of -0.54%. Regarding short-term risk, SMFR is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check ACON's competition here
SMFR vs CMAX Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, SMFR is priced at $0.31, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas CMAX's P/E ratio is -0.00. In terms of profitability, SMFR's ROE is -0.28%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, SMFR is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CMAX's competition here
SMFR vs BFRGW Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, BFRGW has a market cap of 1.5M. Regarding current trading prices, SMFR is priced at $0.31, while BFRGW trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas BFRGW's P/E ratio is -1.00. In terms of profitability, SMFR's ROE is -0.28%, compared to BFRGW's ROE of -2.18%. Regarding short-term risk, SMFR is more volatile compared to BFRGW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check BFRGW's competition here
SMFR vs VSEEW Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, VSEEW has a market cap of 1.5M. Regarding current trading prices, SMFR is priced at $0.31, while VSEEW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas VSEEW's P/E ratio is -0.06. In terms of profitability, SMFR's ROE is -0.28%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, SMFR is more volatile compared to VSEEW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check VSEEW's competition here
SMFR vs LIFWZ Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, SMFR is priced at $0.31, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, SMFR is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check LIFWZ's competition here
SMFR vs EUDAW Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, EUDAW has a market cap of 1M. Regarding current trading prices, SMFR is priced at $0.31, while EUDAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas EUDAW's P/E ratio is 0.03. In terms of profitability, SMFR's ROE is -0.28%, compared to EUDAW's ROE of +0.13%. Regarding short-term risk, SMFR is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check EUDAW's competition here
SMFR vs MSPRZ Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, SMFR is priced at $0.31, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, SMFR is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check MSPRZ's competition here
SMFR vs WORX Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, WORX has a market cap of 303.5K. Regarding current trading prices, SMFR is priced at $0.31, while WORX trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas WORX's P/E ratio is -1.17. In terms of profitability, SMFR's ROE is -0.28%, compared to WORX's ROE of -0.65%. Regarding short-term risk, SMFR is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check WORX's competition here
SMFR vs KERNW Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, SMFR is priced at $0.31, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas KERNW's P/E ratio is -0.00. In terms of profitability, SMFR's ROE is -0.28%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, SMFR is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check KERNW's competition here
SMFR vs KERN Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, SMFR is priced at $0.31, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas KERN's P/E ratio is -0.01. In terms of profitability, SMFR's ROE is -0.28%, compared to KERN's ROE of -0.17%. Regarding short-term risk, SMFR is more volatile compared to KERN. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check KERN's competition here
SMFR vs LIFWW Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, SMFR is priced at $0.31, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas LIFWW's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, SMFR is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check LIFWW's competition here
SMFR vs ZCMD Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, ZCMD has a market cap of 38.9K. Regarding current trading prices, SMFR is priced at $0.31, while ZCMD trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas ZCMD's P/E ratio is -0.04. In terms of profitability, SMFR's ROE is -0.28%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, SMFR is more volatile compared to ZCMD. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check ZCMD's competition here
SMFR vs CMAXW Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, SMFR is priced at $0.31, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas CMAXW's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, SMFR is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CMAXW's competition here
SMFR vs ACONW Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, ACONW has a market cap of 13.2K. Regarding current trading prices, SMFR is priced at $0.31, while ACONW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas ACONW's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to ACONW's ROE of -0.54%. Regarding short-term risk, SMFR is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check ACONW's competition here
SMFR vs SMFRW Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, SMFR is priced at $0.31, while SMFRW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas SMFRW's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to SMFRW's ROE of -0.28%. Regarding short-term risk, SMFR is less volatile compared to SMFRW. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check SMFRW's competition here
SMFR vs CSLT Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, CSLT has a market cap of 0. Regarding current trading prices, SMFR is priced at $0.31, while CSLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas CSLT's P/E ratio is -37.27. In terms of profitability, SMFR's ROE is -0.28%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, SMFR is more volatile compared to CSLT. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CSLT's competition here
SMFR vs MSPRV Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, SMFR is priced at $0.31, while MSPRV trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas MSPRV's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to MSPRV's ROE of N/A. Regarding short-term risk, SMFR is less volatile compared to MSPRV. This indicates potentially lower risk in terms of short-term price fluctuations for SMFR.Check MSPRV's competition here
SMFR vs CNVY Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, SMFR is priced at $0.31, while CNVY trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas CNVY's P/E ratio is -71.50. In terms of profitability, SMFR's ROE is -0.28%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, SMFR is more volatile compared to CNVY. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CNVY's competition here
SMFR vs CHNG Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, SMFR is priced at $0.31, while CHNG trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas CHNG's P/E ratio is -152.72. In terms of profitability, SMFR's ROE is -0.28%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, SMFR is more volatile compared to CHNG. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CHNG's competition here
SMFR vs CERN Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, CERN has a market cap of 0. Regarding current trading prices, SMFR is priced at $0.31, while CERN trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas CERN's P/E ratio is 55.84. In terms of profitability, SMFR's ROE is -0.28%, compared to CERN's ROE of +0.14%. Regarding short-term risk, SMFR is more volatile compared to CERN. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check CERN's competition here
SMFR vs MTBC Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, SMFR is priced at $0.31, while MTBC trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas MTBC's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to MTBC's ROE of +0.17%. Regarding short-term risk, SMFR is more volatile compared to MTBC. This indicates potentially higher risk in terms of short-term price fluctuations for SMFR.Check MTBC's competition here
SMFR vs NAVA Comparison July 2026
SMFR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMFR stands at 246.4M. In comparison, NAVA has a market cap of 0. Regarding current trading prices, SMFR is priced at $0.31, while NAVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMFR currently has a P/E ratio of N/A, whereas NAVA's P/E ratio is N/A. In terms of profitability, SMFR's ROE is -0.28%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, Volatility data is not available for a full comparison. SMFR has daily volatility of 25.47 and NAVA has daily volatility of N/A.Check NAVA's competition here